We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Merck and Co Inc | NYSE:MRK | NYSE | Common Stock |
Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
-0.0285 | -0.02% | 128.7715 | 129.76 | 128.475 | 129.76 | 2,218,989 | 17:27:27 |
By Dean Seal
AstraZeneca PLC and Merck & Co. said Friday that long-term follow-up results for trials of its Lynparza treatment showed improved long-term survival for patients with advanced ovarian cancer.
The companies, which jointly developed and commercialized the medication, said a five-year follow-up of one trial showed 65.5% survival in patients treated with Lynparza combined with bevacizumab compared with 48.4% survival in a group given bevacizumab and a placebo.
A seven-year follow-up of another trial showed 67% survival in advanced ovarian cancer patients with BRCA mutations who received Lynparza, compared with 47% in a placebo group.
Susan Galbraith, AstraZeneca's executive vice president of oncology research and development, said the five-year survival rate of newly diagnosed patients with advanced ovarian cancer is 30% to 50%.
"In that context, it is phenomenal to share the long-term overall survival data from both PAOLA-1 and SOLO-1, with two out of three patients still alive in these trials," she said.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
September 09, 2022 08:56 ET (12:56 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year Merck Chart |
1 Month Merck Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions